Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2009 (2009), Article ID 241390, 7 pages
Research Article

Construction of a Recombinant Eukaryotic Expression Plasmid Containing Human Calcitonin Gene and Its Expression in NIH3T3 Cells

1Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China
2Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
3Department of Gynecology, International Peaceful Healthcare Hospital for Women & Children of China, Welfare Institute, Shanghai Jiao Tong University, Shanghai 200230, China
4Department of Orthopedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China

Received 11 February 2009; Revised 10 May 2009; Accepted 11 June 2009

Academic Editor: Wuyuan Lu

Copyright © 2009 Xiaolin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. K. Craig, L. Hall, and M. R. Edbrooke, “Partial nucleotide sequence of human calcitonin precursor mRNA identifies flanking cryptic peptides,” Nature, vol. 295, no. 5847, pp. 345–347, 1982. View at Google Scholar
  2. J. Allison, L. Hall, I. MacIntyre, and R. K. Craig, “The construction and partial characterization of plasmids containing complementary DNA sequences to human calcitonin precursor polyprotein,” Biochemical Journal, vol. 199, no. 3, pp. 725–731, 1981. View at Google Scholar
  3. M. Munoz-Torres, G. Alonso, and M. P. Raya, “Calcitonin therapy in osteoporosis,” Treatments in Endocrinology, vol. 3, no. 2, pp. 117–132, 2004. View at Publisher · View at Google Scholar
  4. S. Konno and S. Kikuchi, “Therapeutic effects of calcitonin on back pain in the patients with osteoporosis,” Clinical Calcium, vol. 15, no. 3, pp. 168–173, 2005. View at Google Scholar
  5. NIH Consensus Development Panel, “Osteoporosis prevention, diagnosis, and therapy,” The Journal of the American Medical Association, vol. 285, pp. 785–795, 2001. View at Google Scholar
  6. N. Li, P. Ou, H. Zhu et al., “Prevalence rate of osteoporosis in the mid aged and elderly in selectedparts of China,” Chinese Medical Journal, vol. 115, pp. 773–775, 2002. View at Google Scholar
  7. D. Felsenberg and S. Boonen, “The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management,” Clinical Therapeutics, vol. 27, no. 1, pp. 1–11, 2005. View at Publisher · View at Google Scholar
  8. J. M. Lane, E. H. Riley, and P. Z. Wirganowicz, “Osteoporosis: diagnosis and treatment,” Journal of Bone and Joint Surgery, vol. 78, no. 4, pp. 618–632, 1996. View at Google Scholar
  9. L. S. Lim and P. Y. Takahashi, “Osteoporosis intervention in men with hip fracture,” Age and Ageing, vol. 33, no. 5, pp. 507–508, 2004. View at Publisher · View at Google Scholar
  10. L. B. Tanko, Y. Z. Bagger, P. Alexandersen et al., “Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover,” Journal of Bone and Mineral Research, vol. 19, no. 9, pp. 1531–1538, 2004. View at Publisher · View at Google Scholar
  11. S. Merli, S. De Falco, A. Verdoliva et al., “An expression system for the single-step production of recombinant human amidated calcitonin,” Protein Expression and Purification, vol. 7, no. 4, pp. 347–354, 1996. View at Publisher · View at Google Scholar
  12. N. Dursun, E. Dursun, and S. Yalcin, “Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis,” International Journal of Clinical Practice, vol. 55, no. 8, pp. 505–509, 2001. View at Google Scholar
  13. N. N. Aldini, P. Caliceti, S. Lora et al., “Calcitonin release system in the treatment of experimental osteoporosis. Histomorphometric evaluation,” Journal of Orthopaedic Research, vol. 19, no. 5, pp. 955–961, 2001. View at Publisher · View at Google Scholar
  14. C. Chakraborty, S. Nandi, and S. Sinha, “Overexpression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in streptomyces avermitilis,” Protein and Peptide Letters, vol. 11, no. 2, pp. 165–173, 2004. View at Publisher · View at Google Scholar
  15. C. Chakraborty, S. S. Nandi, B. Sarkar, and S. Sinha, “Overexpression and purification of recombinant eel calcitonin and its phylogenetic analysis,” Protein and Peptide Letters, vol. 12, no. 3, pp. 263–269, 2005. View at Publisher · View at Google Scholar
  16. M. J. Coloma, A. Hastings, L. A. Wims, and S. L. Morrison, “Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction,” Journal of Immunological Methods, vol. 152, no. 1, pp. 89–104, 1992. View at Publisher · View at Google Scholar
  17. C. W. Dieffenbach and G. S. Bveksler, PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, NY, USA, 1995.
  18. J. Sambrook, E. F. Fritsch, and T. Maniatis, Molecular Cloning, Cold Spring Harbar Laboratory, New York, NY, USA, 2nd edition, 1989.
  19. N. Takahashi, H. Yamana, S. Yoshiki et al., “Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures,” Endocrinology, vol. 122, no. 4, pp. 1373–1382, 1988. View at Google Scholar
  20. M. T. McDermott and G. S. Kidd, “The role of calcitonin in the development and treatment of osteoporosis,” Endocrine Reviews, vol. 8, no. 4, pp. 377–390, 1987. View at Google Scholar
  21. S. Patel, A. R. Lyons, and D. J. Hosking, “Drugs used in the treatment of metabolic bone disease: clinical pharmacology and therapeutic use,” Drugs, vol. 46, no. 4, pp. 594–617, 1993. View at Google Scholar
  22. G. J. Cote, D. T. Stolow, S. Peleg, S. M. Berget, and R. F. Gagel, “Identification of exon sequences and an exon binding protein involved in alternative RNA splicing of calcitonin/CGRP,” Nucleic Acids Research, vol. 20, no. 9, pp. 2361–2366, 1992. View at Google Scholar
  23. R. Giardino, M. Fini, N. Nicoli Aldini et al., “Effects of synthetic salmon calcitonin and alendronate on bone quality in ovariectomized rats,” Minerva Medica, vol. 88, no. 11, pp. 469–477, 1997. View at Google Scholar
  24. P. L. Robert and L. C. William, “Transplantation of encapsulated cells and tissues,” Surgery, vol. 121, no. 1, pp. 1–9, 1997. View at Publisher · View at Google Scholar
  25. I. T. Tai and A. M. Sun, “Microencapsulation of recombinant cells: a new delivery system for gene therapy,” The FASEB Journal, vol. 7, no. 11, pp. 1061–1069, 1993. View at Google Scholar